HWM
ADMA icon

HighMark Wealth Management’s ADMA Biologics ADMA Stock Holding History

HighMark Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-885
Closed -$13K – 589
2025
Q3 		$13K Buy
+885
New +$15.2K 0.01% 271

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighMark Wealth Management's ADMA Position: Q4 2025 in Review

HighMark Wealth Management sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 885 shares — an estimated $13K sold.

HighMark Wealth Management first reported a position in ADMA in Q3 2025 and held it in 1 quarter. The position peaked at $13K in Q3 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • HighMark Wealth Management reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • HighMark Wealth Management sold 885 ADMA Biologics shares in Q4 2025, an estimated $13K.
  • HighMark Wealth Management first reported a position in ADMA Biologics in Q3 2025 and held it in 1 quarter.
  • HighMark Wealth Management's ADMA Biologics position peaked at $13K in Q3 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on HighMark Wealth Management's 13F filing for Q4 2025, filed 5 Feb 2026.